|
| |||||||||||||||||||||||||||||||||||||||||
On the basis of current knowledge, we agree with Dr. Marijon and colleagues (Aug. 2 issue)5 that morphologic valve changes, in addition to Doppler regurgitation, are necessary to define rheumatic heart disease in a setting in which most subjects are asymptomatic. More studies are needed to further define the minimal valvular morphologic characteristics of subclinical rheumatic heart disease. To this end, it would be helpful if the authors could describe in detail the specific criteria they used to determine "restricted leaflet mobility, focal or generalized valvular thickening, and abnormal subvalvular thickening."
It is also important to follow the natural history of isolated pathologic regurgitation detected by echocardiographic screening, such as that reported by Marijon et al. in 66 children in Mozambique.4 This will assist clinicians who must decide whether to commence prophylaxis with penicillin G benzathine in such patients.
Rachel Webb, M.B., Ch.B.
University of Auckland
Auckland 1142, New Zealand
Nigel J. Wilson, F.R.A.C.P.
Starship Children's Hospital
Auckland 1023, New Zealand
Diana Lennon, F.R.A.C.P.
University of Auckland
Auckland 1142, New Zealand
References
With regard to echocardiographic criteria for subclinical rheumatic features, the boundary between physiologic valve regurgitation and authentic but minimal rheumatic lesions remains difficult to discern in some cases.2 The study of both Doppler and morphologic criteria enhances the specificity of echocardiography in this setting. Morphologic criteria in our study were based on the assessment of leaflet morphology, showing a typical marked thickening of the margins; leaflet mobility, with abnormal motion due to the posterior leaflet tip restriction; and subvalvular apparatus, displaying prominent thickening (most often just below the valve) and shortening of chordal structures. Using these criteria, we were able to document an excellent level of interobserver agreement for the detection of early rheumatic valve disease.
Eloi Marijon, M.D.
European Georges Pompidou Hospital
75908 Paris CEDEX 15, France
eloi_marijon{at}yahoo.fr
David S. Celermajer, Ph.D.
University of Sydney
Sydney, NSW 2006, Australia
Xavier Jouven, M.D., Ph.D.
INSERM Unité 780 Avenir
94804 Villejuif, France
References
| |||||||||||||||||||||||||||||||||||||||||
HOME | SUBSCRIBE | SEARCH | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | PRIVACY | TERMS OF USE | HELP | beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved. |